[go: up one dir, main page]

NO20016067D0 - Fremgangsmåte for fremstilling av IL-8-reseptor-antagonister - Google Patents

Fremgangsmåte for fremstilling av IL-8-reseptor-antagonister

Info

Publication number
NO20016067D0
NO20016067D0 NO20016067A NO20016067A NO20016067D0 NO 20016067 D0 NO20016067 D0 NO 20016067D0 NO 20016067 A NO20016067 A NO 20016067A NO 20016067 A NO20016067 A NO 20016067A NO 20016067 D0 NO20016067 D0 NO 20016067D0
Authority
NO
Norway
Prior art keywords
preparation
receptor antagonists
antagonists
receptor
Prior art date
Application number
NO20016067A
Other languages
English (en)
Other versions
NO20016067L (no
NO314301B1 (no
Inventor
Deborah Lynn Bryan
John Gerald Gleason
Katherine Louisa Widdowson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20016067L publication Critical patent/NO20016067L/no
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20016067D0 publication Critical patent/NO20016067D0/no
Publication of NO314301B1 publication Critical patent/NO314301B1/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20016067A 1996-08-15 2001-12-12 Fremgangsmåte for fremstilling av IL-8-reseptor-antagonister NO314301B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2341496P 1996-08-15 1996-08-15
PCT/US1997/014581 WO1998006397A1 (en) 1996-08-15 1997-08-15 Il-8 receptor antagonists

Publications (3)

Publication Number Publication Date
NO20016067L NO20016067L (no) 1999-04-12
NO20016067D0 true NO20016067D0 (no) 2001-12-12
NO314301B1 NO314301B1 (no) 2003-03-03

Family

ID=21814968

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19990668A NO312458B1 (no) 1996-08-15 1999-02-12 IL-8-reseptor antagonister, fremgangsmåte for fremstilling derav og farmasöytisk preparat
NO20016067A NO314301B1 (no) 1996-08-15 2001-12-12 Fremgangsmåte for fremstilling av IL-8-reseptor-antagonister

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19990668A NO312458B1 (no) 1996-08-15 1999-02-12 IL-8-reseptor antagonister, fremgangsmåte for fremstilling derav og farmasöytisk preparat

Country Status (18)

Country Link
US (1) US6204294B1 (no)
EP (1) EP0929302A4 (no)
JP (1) JP2000516619A (no)
KR (1) KR20000030003A (no)
CN (1) CN1152675C (no)
AR (1) AR008290A1 (no)
AU (1) AU723816B2 (no)
BR (1) BR9711140A (no)
CA (1) CA2263388A1 (no)
CO (1) CO5031286A1 (no)
CZ (1) CZ46799A3 (no)
IL (1) IL128501A0 (no)
NO (2) NO312458B1 (no)
PL (1) PL331539A1 (no)
TR (1) TR199900318T2 (no)
TW (1) TW461878B (no)
WO (1) WO1998006397A1 (no)
ZA (1) ZA977301B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2255858C (en) 1996-05-24 2007-09-11 Neurosearch A/S Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
WO1997049400A1 (en) 1996-06-27 1997-12-31 Smithkline Beecham Corporation Il-8 receptor antagonists
WO1998006399A1 (en) * 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
CA2245224A1 (en) * 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
WO1999047158A2 (en) 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
CA2305787A1 (en) * 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
AR029361A1 (es) * 1999-05-28 2003-06-25 Smithkline Beecham Corp Compuestos de guanidina ciclicas antagonistas de los receptores de la il- 8, composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento
AR029637A1 (es) * 1999-05-28 2003-07-10 Smithkline Beecham Corp Compuestos de guanidina, antagonistas de los receptores de la il-8, una composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de un medicamento
ECSP003525A (es) * 1999-06-16 2002-01-25 Smithkline Beecham Corp Antagonistas del receptor de il- 8 iv
UY26627A1 (es) * 2000-03-24 2001-09-28 Smithkline Beecham Corp Antagonistas de receptores de il-8
US7378098B2 (en) * 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20050059584A1 (en) * 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
CA2335109A1 (en) * 2000-04-12 2001-10-12 Chemokine Therapeutics Corporation Cxcr4 agonist treatment of hematopoietic cells
US7368425B2 (en) * 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
WO2001079168A1 (en) 2000-04-14 2001-10-25 Kureha Chemical Industry Co., Ltd. Nitrogenous compounds and antiviral drugs containing the same
US6515001B2 (en) 2001-03-05 2003-02-04 Chemokine Therapeutic Corporation IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
CN1630517A (zh) * 2001-05-24 2005-06-22 吴羽化学工业株式会社 包含含氮化合物的具有cxcr4拮抗作用的药物
US7176227B2 (en) 2002-09-11 2007-02-13 Kureha Corporation Amine compounds and use thereof
TW200418812A (en) * 2002-10-29 2004-10-01 Smithkline Beecham Corp IL-8 receptor antagonists
CA2558600C (en) * 2004-03-10 2013-07-09 Kureha Corporation A substituted-trialkyl amine compound with anti-viral activity based on antagonism against a chemokine receptor cxcr4
MXPA06013118A (es) 2004-05-12 2007-02-28 Schering Corp Antagonistas de cxcr1 y cxcr2 de quimocina.
EP1634573A1 (en) * 2004-08-16 2006-03-15 The Procter and Gamble Company 2-(Amino or substituted Amino)-5,6-substituted Phenol compounds, dyeing compositions containing them, and use thereof
WO2006023435A1 (en) * 2004-08-16 2006-03-02 The Procter & Gamble Company 2-(amino or substituted amino)-5, 6-substituted phenol compounds, dyeing compositions containing them, and use thereof
EP1812008A4 (en) * 2004-10-20 2008-10-29 Smithkline Beecham Corp ANTAGONISTS OF THE IL-8 RECEPTOR
JP2009534420A (ja) * 2006-04-21 2009-09-24 スミスクライン・ビーチャム・コーポレイション Il−8受容体アンタゴニスト
WO2007124424A2 (en) * 2006-04-21 2007-11-01 Smithkline Beecham Corporation Il-8 receptor antagonists
PE20080943A1 (es) * 2006-06-23 2008-09-27 Smithkline Beecham Corp Sal toluenosulfonato de 4-{[6-cloro-3-({[(2-cloro-3-fluorofenil)amino]carbonil}amino)-2-hidroxifenil]sulfonil}-1-piperazinacarboxilato de 1,1-dimetiletilo como antagonista del receptor de il-8

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US537186A (en) * 1895-04-09 Jacob ebert
US4269837A (en) * 1980-02-19 1981-05-26 Pfizer Inc. Hypoglycemic guanylamidines, compositions and use
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
JP2742084B2 (ja) * 1989-03-13 1998-04-22 キヤノン株式会社 グアニジン二量化物およびグアニジン二量化物を含有する静電荷像現像用トナー
US5214208A (en) * 1989-03-13 1993-05-25 Canon Kabushiki Kaisha Toner containing a dimer of diarylguanidine type compound for developing electrostatic image
US5792444A (en) * 1989-05-09 1998-08-11 The General Hospital Corporation Labeled chemotactic peptides to image focal sites of infection or inflammation
US5371086A (en) 1991-03-15 1994-12-06 The Green Cross Corporation Aminopyridine compounds
AU4530693A (en) 1992-08-13 1994-03-15 Upjohn Company, The Cyanoguanidines as potassium channel blockers
DK41193D0 (da) * 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
US5401758A (en) * 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds

Also Published As

Publication number Publication date
NO20016067L (no) 1999-04-12
CN1232398A (zh) 1999-10-20
PL331539A1 (en) 1999-07-19
US6204294B1 (en) 2001-03-20
IL128501A0 (en) 2000-01-31
EP0929302A1 (en) 1999-07-21
NO314301B1 (no) 2003-03-03
NO990668D0 (no) 1999-02-12
TW461878B (en) 2001-11-01
CO5031286A1 (es) 2001-04-27
WO1998006397A1 (en) 1998-02-19
KR20000030003A (ko) 2000-05-25
CZ46799A3 (cs) 1999-12-15
ZA977301B (en) 1998-02-16
JP2000516619A (ja) 2000-12-12
AU723816B2 (en) 2000-09-07
CN1152675C (zh) 2004-06-09
BR9711140A (pt) 1999-08-17
TR199900318T2 (xx) 1999-05-21
EP0929302A4 (en) 2002-10-31
NO312458B1 (no) 2002-05-13
CA2263388A1 (en) 1998-02-19
NO990668L (no) 1999-04-12
AU4075097A (en) 1998-03-06
AR008290A1 (es) 1999-12-29

Similar Documents

Publication Publication Date Title
NO20016067D0 (no) Fremgangsmåte for fremstilling av IL-8-reseptor-antagonister
NO983737D0 (no) IL-8 reseptor antagonister
PL339134A1 (en) Antagonists of il-8 receptor
PL334756A1 (en) Antagonists of il-8 receptor
BR9709952A (pt) Antagonistas de receptor de il-8
NO986109D0 (no) IL-8 reseptor-antagonister
MA24361A1 (fr) Procede pouyr la preparation d'antagonistes de recepteur de vitronectine
NO972016D0 (no) Indolyl-Y-reseptorantagonister
BR9612327A (pt) Antagonistas receptores de vitronectina
EP0810994A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
EP0866705A4 (en) FIBRINOGENIC RECEPTOR ANTAGONISTS
ID16742A (id) Antagonis reseptor endotelin
PT1036072E (pt) Antagonistas de receptores de trombina
PL334774A1 (en) Antagonists of il-8 receptor
PL339133A1 (en) Antagonists of il-8 receptor
PL330708A1 (en) Derivatives of indolydine useful as antagonists of 5-ht-2c receptor
DE69824837D1 (de) Il-8-rezeptor-antagonisten
NO993065L (no) Fremgangsmåte for fremstilling av NMDA-antagonister
NO20004422D0 (no) FremgangsmÕte for fremstilling av sulfanyl-type endothelinreseptor-antagonister
EP0957908A4 (en) FIBRINOGEN RECEPTOR ANTAGONISTS
NO955296D0 (no) Fremgangsmåte for fremstilling av betongkonstruksjon
IL141121A0 (en) Il-8 receptor antagonists

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees